OTCPK:CLIF.F

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Cordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, Macau, India, Malaysia, Indonesia, Myanmar, Vietnam, the Philippines, Bangladesh, and internationally. More Details


Snowflake Analysis

Undervalued with excellent balance sheet.

Share Price & News

How has Cordlife Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CLIF.F has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

CLIF.F

-2.3%

US Healthcare

-0.8%

US Market


1 Year Return

n/a

CLIF.F

21.0%

US Healthcare

13.8%

US Market

Return vs Industry: Insufficient data to determine how CLIF.F performed against the US Healthcare industry.

Return vs Market: Insufficient data to determine how CLIF.F performed against the US Market.


Shareholder returns

CLIF.FIndustryMarket
7 Day0%-2.3%-0.8%
30 Day0%-4.9%-5.7%
90 Day-10.7%0.4%8.6%
1 Yearn/a22.6%21.0%16.4%13.8%
3 Yearn/a23.9%18.5%36.9%27.8%
5 Year-71.6%-71.6%50.0%39.4%85.0%64.2%

Price Volatility Vs. Market

How volatile is Cordlife Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Cordlife Group undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CLIF.F ($0.25) is trading below our estimate of fair value ($1.32)

Significantly Below Fair Value: CLIF.F is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CLIF.F is good value based on its PE Ratio (12.3x) compared to the US Healthcare industry average (22.2x).

PE vs Market: CLIF.F is good value based on its PE Ratio (12.3x) compared to the US market (17.6x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CLIF.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CLIF.F is good value based on its PB Ratio (0.7x) compared to the US Healthcare industry average (2.8x).


Next Steps

Future Growth

How is Cordlife Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

13.9%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cordlife Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Examine whether Cordlife Group is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on theOTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Cordlife Group's filings and announcementshere.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Cordlife Group performed over the past 5 years?

-51.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CLIF.F has high quality earnings.

Growing Profit Margin: CLIF.F's current net profit margins (12.7%) are higher than last year (3.8%).


Past Earnings Growth Analysis

Earnings Trend: CLIF.F's earnings have declined by 51.2% per year over the past 5 years.

Accelerating Growth: CLIF.F's earnings growth over the past year (224.8%) exceeds its 5-year average (-51.2% per year).

Earnings vs Industry: CLIF.F earnings growth over the past year (224.8%) exceeded the Healthcare industry 31.1%.


Return on Equity

High ROE: CLIF.F's Return on Equity (5.6%) is considered low.


Next Steps

Financial Health

How is Cordlife Group's financial position?


Financial Position Analysis

Short Term Liabilities: CLIF.F's short term assets (SGD99.9M) exceed its short term liabilities (SGD28.1M).

Long Term Liabilities: CLIF.F's short term assets (SGD99.9M) exceed its long term liabilities (SGD72.9M).


Debt to Equity History and Analysis

Debt Level: CLIF.F's debt to equity ratio (3.1%) is considered satisfactory.

Reducing Debt: CLIF.F's debt to equity ratio has reduced from 79.8% to 3.1% over the past 5 years.

Debt Coverage: CLIF.F's debt is well covered by operating cash flow (334.7%).

Interest Coverage: Insufficient data to determine if CLIF.F's interest payments on its debt are well covered by EBIT.


Balance Sheet


Next Steps

Dividend

What is Cordlife Group current dividend yield, its reliability and sustainability?

2.82%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: CLIF.F's dividend (2.82%) is higher than the bottom 25% of dividend payers in the US market (1.72%).

High Dividend: CLIF.F's dividend (2.82%) is low compared to the top 25% of dividend payers in the US market (4.94%).


Stability and Growth of Payments

Stable Dividend: CLIF.F has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: CLIF.F has only been paying a dividend for 8 years, and since then payments have fallen.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (34.5%), CLIF.F's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average management tenure


CEO

Poh Lan Tan (58 yo)

1.58yrs

Tenure

Ms. Poh Lan Tan has been Group Chief Executive Officer and Executive Director at Cordlife Group Limited since February 28, 2019 and served as its Group Chief Operating Officer since April 12, 2016 until 20 ...


Leadership Team

NamePositionTenureCompensationOwnership
Poh Lan Tan
Group CEO & Executive Director1.58yrsno data0.21%
SGD 137.6k
Boon Yong Choo
Group Chief Financial Officer3.58yrsno datano data
Huiying Tan
Group Director of Quality & Operations6.17yrsno datano data
Andrew Ekaputra
Group Technical Directorno datano datano data
Siew Koon Ang
Company Secretaryno datano datano data
Janice Ong
Country Chief Executive Officer of Cordlife Singaporeno datano datano data
Upamannyue Chowdhury
Country Chief Executive Officer of Cordlife Indiano datano datano data
Lucy Lai
Country Chief Executive Officer of Healthbaby Hong Kong- Cordlife Hong Kongno datano datano data
Raymond Wong
Country Chief Executive Officer of Stemlife Malaysiano datano datano data
Michael Arnonobal
Country Chief Executive Officer of Cordlife Philippinesno datano datano data
Retno Suprihatin
Country Chief Executive Officer of Cordlife Idonesiano datano datano data
Hnin Yi Thet
Group Finance Director3.58yrsno data0.18%
SGD 116.4k

3.6yrs

Average Tenure

44yo

Average Age

Experienced Management: CLIF.F's management team is considered experienced (3.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Poh Lan Tan
Group CEO & Executive Director1.58yrsno data0.21%
SGD 137.6k
Jin Hian Goh
Independent Chairman2.42yrsS$118.00kno data
Chi Wah Fong
Non-Independent Non-Executive Director1.67yrsno datano data
Choon Hou Ho
Independent Vice Chairman3.83yrsS$100.00k0.31%
SGD 204.0k
Wai Leung Wong
Independent Director6yrsS$83.00kno data
Ling Yun Zhai
Non-Independent Non-Executive Director0.75yrno datano data
Hwee Yeo
Independent Director2.33yrsS$83.00kno data
Lin Wang
Non-Independent Non-Executive Director0.83yrno datano data
Chien Chang
Non-Independent Non-Executive Director0.75yrno datano data

1.7yrs

Average Tenure

51yo

Average Age

Experienced Board: CLIF.F's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Cordlife Group Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cordlife Group Limited
  • Ticker: CLIF.F
  • Exchange: OTCPK
  • Founded: 2001
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: S$90.377m
  • Listing Market Cap: S$65.558m
  • Shares outstanding: 254.58m
  • Website: https://www.cordlife.com

Location

  • Cordlife Group Limited
  • A’Posh Bizhub
  • No. 06-01/09, 1 Yishun Ind. St 1
  • Singapore
  • 768160
  • Singapore

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
P8ASGX (Singapore Exchange)YesOrdinary SharesSGSGDMar 2012
3DCBST (Boerse-Stuttgart)YesOrdinary SharesDEEURMar 2012
CLIF.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDMar 2012

Biography

Cordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, Macau, India, Malaysia, Indonesia, Myanmar, Vietnam, the Philippines, Bangladesh, and in ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/28 04:54
End of Day Share Price2020/08/20 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.